Grip Strength Evaluated as Aging Marker for Unregulated Gene Therapies
Clinics outside regulated markets offer AAV gene therapies delivered locally to muscle or brain, including follistatin, VEGF, telomerase, and SIRT1. Triple Helix researchers report using grip strength as an aging biomarker to assess outcomes from these therapies. The article notes that validating biomarkers is difficult because their behavior may change after regenerative or anti-aging interventions.
Clinics in medical-tourism markets beyond the US and Europe provide AAV-based gene treatments, often using AAV8 or AAV9. Delivery is typically intramuscular for muscle or intranasal for brain effects. Genes include follistatin, VEGF, telomerase, and SIRT1. Local low-dose use is described as relatively safe, unlike high systemic doses linked to dangerous immune reactions.
Triple Helix researchers report using grip strength to track outcomes. Grip strength predicts mortality, cognitive decline, disability, hospitalization, and quality of life, and remains predictive after adjusting for lean mass. A key difficulty is that a biomarker validated in normal aging may behave differently after regenerative or anti-aging interventions, so diverse therapies are needed to test it.
People considering medical-tourism gene therapies may rely on grip-strength claims as evidence, though biomarker validation remains uncertain. Researchers and clinicians could gain hypotheses from this unregulated experience, while regulators may face pressure to assess local AAV uses. If outcomes are overstated, patients could bear health risks and financial costs; if carefully documented, the field may learn how aging markers respond to interventions.